Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults –

Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Actual Study Start Date  :August 28, 2020
Actual Primary Completion Date  :March 5, 2021
Estimated Study Completion Date  :February 14, 2023